Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 6/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24390489 | 1.00 | CASP2 (0.53) | CASP2NOD1FAAHSLC6A5NAAA | |
| SCHEMBL15084766 | 0.87 | NOD1 (0.63) | CASP2NOD1FAAHSLC6A5NAAA | |
| SCHEMBL24796256 | 0.87 | CASP2 (0.54) | CASP2NOD1FAAHSLC6A5NAAA | |
| SCHEMBL25878467 | 0.87 | CASP2 (0.54) | CASP2NOD1FAAHSLC6A5NAAA | |
| SCHEMBL20471131 | 0.85 | ALB (0.61) | CASP2NOD1FAAHSLC6A5NAAA | |
| SCHEMBL21389124 | 0.85 | CASP2 (0.51) | CASP2NOD1FAAHSLC6A5NAAA | |
| SCHEMBL17244834 | 0.83 | ALB (0.44) | CASP2NOD1NAAATLR2SIRT6 | |
| SCHEMBL22386556 | 0.83 | NAAA (0.61) | CASP2NOD1FAAHNAAADNM1 | |
| SCHEMBL22646981 | 0.81 | NOD1 (0.59) | CASP2NOD1FAAHSLC6A5NAAA | |
| SCHEMBL13120985 | 0.81 | CASP2 (0.57) | CASP2NOD1FAAHSLC6A5NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346961-A1 | GLP-1 AND GIP RECEPTOR CO-AGONISTS | NOVO NORDISK A/S (DK) | 2023-11-02 | — | — | US | disclosed |
| WO-2022090447-A1 | GLP-1, GIP AND GLUCAGON RECEPTOR TRIPLE AGONISTS | NOVO NORDISK A/S (DK) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346961-A1 | GLP-1 AND GIP RECEPTOR CO-AGONISTS | GLP1R, GIPR, GCGR | CASP2 3431/4885NOD1 1309/4885FAAH 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.